尿中Ｎ‐ａｃｅｔｙｌ‐β‐Ｄ‐ｇｌｕｃｏｓａｍｉｎｉｄａｓｅ（ＮＡＧ）により示されたＩＩ型糖尿病の早期腎障害に対するＤｉｌａｚｅｐ ｄｉｈｙｄｒｏｃｈｌｏｒｉｄｅ投与効果の検討

Abstract

Forty-two patients (19 men, 23 women) with NIDDM recruited from the out-patient clinic were studied to evaluate the effect of dilazep dihydrochloride (dilazep) on abnormal urinary NAG excretion. All patients, who showed persistently high NAG excretion in urine, had no other complications including hypertension, proteinuria, and clinically significant retinopathy. Patients whose HbAic or fasting plasma glucose levels had been altered over 10% of pre-administration levels throughout the observation period were excluded. The mean age was 57±12 yr (range 29-75). Blood and urinary analyses were attained before, at one month, three months, and six months after the administration of dilazep (300mg/day). In three months, urinary NAG/Cr ratio as well as NAG concentra tion were significantly reduced (P<0.001). This effect has been observed throughout the observation period of six months. No adverse effects were observed in our patients. These results suggest that dilazep is a useful drug for the improvement of latent diabetic nephropathy indicated by the abnormal NAG excretion in urine.